VX1 vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

VX1

by Volta Medical

EchoNext

by Pathway Labs

AI Verdict

VX1 and EchoNext are both FDA-cleared AI tools in cardiology, but they serve different purposes. VX1 assists electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures by identifying dispersed electrograms. EchoNext, on the other hand, analyzes standard ECGs to detect hidden structural heart disease like heart failure, valve disease, and pulmonary hypertension, acting as a screening tool for earlier detection.

Choose VX1 if…

Choose VX1 if your cardiology practice or hospital focuses on advanced electrophysiology procedures and aims to enhance the precision and standardization of atrial fibrillation and atrial tachycardia ablations. This AI software is ideal for real-time assistance during complex cardiac surgeries, helping to identify dispersed electrograms and potentially reduce inter-operator variability. It's best suited for EP labs seeking to integrate AI directly into their existing mapping and recording systems for immediate surgical guidance.

View VX1 →

Choose EchoNext if…

Choose EchoNext if your healthcare facility, from major hospitals to community practices, needs a non-invasive, cost-effective tool for early detection of hidden structural heart disease using standard ECGs. This AI solution is perfect for broad screening and risk identification of conditions like heart failure, valve disease, and pulmonary hypertension in a wide patient population. It's particularly beneficial for practices looking to integrate AI-powered diagnostic support through a clinical decision support platform like OpenEvidence, with flexible pricing tiers to accommodate different organizational sizes.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	VX1	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

VX1

VX1 offers a simple color-coded interface with visual and sound cues for real-time identification of dispersed electrograms during ablation procedures, which directly assists cardiologists in the operating room. EchoNext, while providing valuable diagnostic support, is integrated into a clinical decision support platform, which may involve a less direct interaction for the end-user compared to real-time procedural guidance.

Clinical Value

EchoNext

EchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI, and has been credited with leading to the first heart transplant attributable to AI-based disease detection. VX1 standardizes electrogram-based ablation outcomes for persistent atrial fibrillation and has shown high rates of freedom from AF post-procedure, but EchoNext's ability to detect hidden conditions earlier across a broader patient population presents a higher clinical impact.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, including details on implementation fees and annual discounts, making its cost structure clear to potential buyers. VX1's pricing is listed as 'contact for pricing,' which lacks transparency and makes it difficult to assess its value proposition without direct inquiry. EchoNext's broad applicability to standard ECGs also suggests a wider potential for cost-effective screening.

Enterprise Readiness

EchoNext

EchoNext explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA), which are crucial for enterprise adoption in healthcare. It is also designed for broad access, from major hospitals to community practices, and is available through the OpenEvidence clinical decision support platform, used by a significant number of U.S. physicians. VX1 does not explicitly state HIPAA compliance or BAA availability in its provided information, which could be a barrier for larger healthcare systems.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. VX1 utilizes deep learning algorithms for real-time identification of dispersed electrograms during complex ablation procedures, aiming to standardize outcomes and reduce variability. EchoNext employs AI to detect hidden structural heart disease from standard ECGs, a novel approach to early screening that has outperformed human cardiologists.

Support & Docs

Tie

Both companies provide FDA clearance for their respective tools, indicating a level of regulatory documentation and implied support. However, specific details regarding ongoing customer support, training programs, or comprehensive documentation beyond user manuals are not extensively detailed for either product in the provided information or readily available web searches. Therefore, it is difficult to definitively distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	VX1	EchoNext
Name	VX1	EchoNext
Company	Volta Medical	Pathway Labs
Description	Volta Medical's VX1 is an FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Specialties	Cardiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine
Key Features (Primary Focus)	AI-guided real-time identification of dispersed electrograms (EGMs) during AFib and atrial tachycardia ablation procedures.	AI-powered ECG analysis for detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

Videos

Demos, reviews, and walkthroughs featuring VX1 and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How does each tool integrate into existing clinical workflows for cardiologists and other relevant specialists?

VX1 integrates directly with existing electrophysiology (EP) lab mapping and recording systems, assisting cardiac electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures. EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, which aims to embed its screening output directly into tools physicians already use, avoiding a separate workflow.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

VX1 assists in the real-time identification of dispersed electrograms during AFib and atrial tachycardia ablation procedures, with a study showing it reliably assists operators in detection and auto-tagging. EchoNext demonstrated high accuracy in identifying structural heart problems from ECGs, outperforming cardiologists in a head-to-head comparison (77% accuracy for EchoNext vs. 64% for cardiologists) in a validation study.

What is the learning curve for physicians adopting these AI tools?

VX1's algorithms are trained on a large database of electrograms annotated by expert electrophysiologists, which is stated to allow for a fast learning curve and standardized outcomes across operators. EchoNext is designed to be integrated into existing clinical decision support platforms, suggesting an aim for ease of use within familiar interfaces, and its ability to outperform cardiologists even when they were assisted by AI suggests a lower learning burden for interpreting its output.

What kind of clinical evidence supports the use of these tools?

Volta Medical's VX1 has been evaluated in studies like the Ev-AIFib Study, which demonstrated its feasibility in generating dispersion maps and standardizing ablation outcomes, with patients showing high freedom from AF/AT after one year. EchoNext was trained on over 700,000 to 1.2 million ECG-echocardiogram pairs and validated across multiple hospital systems, with studies published in Nature and Nature Medicine highlighting its accuracy and ability to detect previously undiagnosed heart disease.

How do these tools contribute to standardizing care and reducing inter-operator variability?

VX1 is designed to reduce inter-operator variability and standardize outcomes by providing AI-guided real-time identification of dispersed electrograms during ablation procedures. EchoNext standardizes ECG interpretation across diverse patient populations, aiming to ensure consistent accuracy and efficiency in cardiac screening and reduce inter-observer variability.

What are the considerations for rolling out these tools across multiple sites or a large healthcare system?

VX1's compatibility with most EP recording, 3D navigation systems, and mapping catheters suggests flexibility for multi-site integration within existing EP lab infrastructures. EchoNext's partnership with OpenEvidence, a platform used by over 500,000 physicians, indicates a strategy for broad accessibility and integration into diverse clinical settings, from major hospitals to community practices, without requiring separate systems.

What specific clinical conditions or patient populations are these tools best suited for?

VX1 is specifically designed for cardiac electrophysiologists to assist during atrial fibrillation and atrial tachycardia ablation procedures, focusing on real-time identification of dispersed electrograms. EchoNext is a broader screening tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, making it suitable for a wider range of cardiology, family medicine, hospital medicine, and internal medicine settings.